Ciprofloxacin DPI (BAYQ3939) ( DrugBank: Ciprofloxacin )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
299嚢胞性線維症2

299. 嚢胞性線維症


臨床試験数 : 1,695 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02661438
(ClinicalTrials.gov)
January 12, 201630/12/2015Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation Using PlaceboMulticenter Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation in Subjects With Non-Cystic Fibrosis Bronchiectasis (NCFB) or Chronic Obstructive Pulmonary Disease (COPD) Using Matching PlaceboBronchiectasis;Pulmonary Disease, Chronic ObstructiveDrug: Placebo to Ciprofloxacin DPI (BAYQ3939)BayerNovartisCompleted40 YearsN/AAll46N/AUnited States
2NCT01764841
(ClinicalTrials.gov)
May 2, 20138/1/2013Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.BronchiectasisDrug: Ciprofloxacin DPI (BAYQ3939);Drug: PlaceboBayerNovartisCompleted18 YearsN/AAll416Phase 3United States;Argentina;Australia;Denmark;France;Germany;Israel;Italy;Japan;Latvia;New Zealand;Slovakia;Spain;United Kingdom